Bank of America Corp DE Acquires 96,572 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Bank of America Corp DE lifted its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 23,611.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 96,981 shares of the company's stock after acquiring an additional 96,572 shares during the quarter. Bank of America Corp DE owned approximately 0.15% of Corvus Pharmaceuticals worth $519,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ancora Advisors LLC boosted its position in Corvus Pharmaceuticals by 62.6% during the 4th quarter. Ancora Advisors LLC now owns 37,869 shares of the company's stock worth $203,000 after acquiring an additional 14,584 shares during the period. Acuta Capital Partners LLC acquired a new stake in shares of Corvus Pharmaceuticals during the fourth quarter worth approximately $398,000. Foresite Capital Management VI LLC purchased a new position in Corvus Pharmaceuticals during the fourth quarter valued at approximately $8,460,000. Virtus ETF Advisers LLC purchased a new position in Corvus Pharmaceuticals during the fourth quarter valued at approximately $47,000. Finally, Alpine Global Management LLC acquired a new position in Corvus Pharmaceuticals in the 4th quarter valued at approximately $62,000. Institutional investors and hedge funds own 46.64% of the company's stock.

Corvus Pharmaceuticals Price Performance

Shares of Corvus Pharmaceuticals stock traded down $0.01 during midday trading on Thursday, hitting $4.49. 579,755 shares of the company were exchanged, compared to its average volume of 757,218. The firm has a market cap of $306.08 million, a P/E ratio of -4.83 and a beta of 0.57. Corvus Pharmaceuticals, Inc. has a 52 week low of $1.75 and a 52 week high of $10.00. The firm has a 50 day simple moving average of $3.54 and a 200-day simple moving average of $4.71.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.13). Equities research analysts expect that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on CRVS shares. Mizuho set a $11.00 price target on shares of Corvus Pharmaceuticals and gave the stock an "outperform" rating in a research note on Tuesday, May 20th. HC Wainwright reaffirmed a "buy" rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 26th. Oppenheimer reiterated an "outperform" rating and set a $17.00 price target (up from $15.00) on shares of Corvus Pharmaceuticals in a report on Friday, May 9th. Finally, Wall Street Zen cut Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, May 20th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.00.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.